Foreign vaccine suppliers want protection from potential lawsuits against adverse side effects, but analysts say India is in a better position to bargain now that the second wave is receding, domestic supply is rising and new vaccines are hitting the marketPfizer says won’t make exception for India in its global approach for vaccine supply
Foreign vaccine suppliers want protection from potential lawsuits against adverse side effects, but analysts say India is in a better position to bargain now that the second wave is receding, domestic supply is rising and new vaccines are hitting the market
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
The bank plans to raise up to Rs 500 crore by issue of equity shares to qualified institutional buyers through qualified institutional plac...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment